Drug Interaction Report

GENERALLY AVOID: Drugs that may blunt the growth hormone response to macimorelin such as muscarinic antagonists (e.g., atropine), anti-thyroid agents (e.g., propylthiouracil), and growth hormone products may impact the accuracy of the macimorelin diagnostic test.

MANAGEMENT: Concomitant use of drugs that can blunt the response to macimorelin should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration. The prescribing information recommends discontinuing growth hormone products for at least one week before administering the macimorelin diagnostic test.

ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of macimorelin. According to the product labeling, administration with a liquid meal decreased macimorelin peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 49%, respectively, compared to administration under fasting conditions (i.e., for at least 8 hours).

MANAGEMENT: Macimorelin should be administered after fasting for at least 8 hours.

The recommended maximum number of medicines in the 'growth hormones' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'growth hormones' category:

• Humatrope (somatropin)
• macimorelin

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.